Literature DB >> 20978197

Targeted radiosensitization of cells expressing truncated DNA polymerase {beta}.

Sari Neijenhuis1, Manon Verwijs-Janssen, Lenie J van den Broek, Adrian C Begg, Conchita Vens.   

Abstract

Ionizing radiation (IR) is an effective anticancer treatment, although failures still occur. To improve radiotherapy, tumor-targeted strategies are needed to increase radiosensitivity of tumor cells, without influencing normal tissue radiosensitivity. Base excision repair (BER) and single-strand break repair (SSBR) contribute to the determination of sensitivity to IR. A crucial protein in BER/SSBR is DNA polymerase β (polβ). Aberrant polβ expression is commonly found in human tumors and leads to inhibition of BER. Here, we show that truncated polβ variant (polβ-Δ)-expressing cells depend on homologous recombination (HR) for survival after IR, indicating that a considerable fraction of polβ-Δ-induced lesions are subject to repair by HR. Increased sensitization was found not to result from involvement in DNA-dependent protein kinase-dependent nonhomologous end joining, the other major double-strand break repair pathway. Caffeine and the ATM inhibitor Ku55933 cause polβ-Δ-dependent radiosensitization. Consistent with the observed HR dependence and the known HR-modulating activity of ATM, polβ-Δ-expressing cells showed increased radiosensitization after BRCA2 knockdown that is absent under ATM-inhibited conditions. Our data suggest that treatment with HR modulators is a promising therapeutic strategy for exploiting defects in the BER/SSBR pathway in human tumors. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20978197     DOI: 10.1158/0008-5472.CAN-09-3901

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  Strategies to improve radiotherapy with targeted drugs.

Authors:  Adrian C Begg; Fiona A Stewart; Conchita Vens
Journal:  Nat Rev Cancer       Date:  2011-04       Impact factor: 60.716

Review 2.  The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance.

Authors:  Peter Bouwman; Jos Jonkers
Journal:  Nat Rev Cancer       Date:  2012-09       Impact factor: 60.716

3.  Enhancement of silencing DNA polymerase β on the radiotherapeutic sensitivity of human esophageal carcinoma cell lines.

Authors:  Yuanyuan Wang; Xiaonan Chen; Xuanyu Hu; Ren Zhang; Yuwen Du; Wenqiao Zang; Ziming Dong; Guoqiang Zhao
Journal:  Tumour Biol       Date:  2014-10

Review 4.  Emerging roles of Jab1/CSN5 in DNA damage response, DNA repair, and cancer.

Authors:  Yunbao Pan; Huiling Yang; Francois X Claret
Journal:  Cancer Biol Ther       Date:  2014-02-04       Impact factor: 4.742

Review 5.  Inhibiting homologous recombination for cancer therapy.

Authors:  Sophia B Chernikova; John C Game; J Martin Brown
Journal:  Cancer Biol Ther       Date:  2012-01-15       Impact factor: 4.742

6.  Genome instability caused by a germline mutation in the human DNA repair gene POLB.

Authors:  Robert W Sobol
Journal:  PLoS Genet       Date:  2012-11-08       Impact factor: 5.917

Review 7.  Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways.

Authors:  Meredith A Morgan; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2015-07-01       Impact factor: 13.801

8.  Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.

Authors:  A Peasland; L-Z Wang; E Rowling; S Kyle; T Chen; A Hopkins; W A Cliby; J Sarkaria; G Beale; R J Edmondson; N J Curtin
Journal:  Br J Cancer       Date:  2011-07-05       Impact factor: 7.640

9.  Tight regulation of ubiquitin-mediated DNA damage response by USP3 preserves the functional integrity of hematopoietic stem cells.

Authors:  Cesare Lancini; Paul C M van den Berk; Joseph H A Vissers; Gaetano Gargiulo; Ji-Ying Song; Danielle Hulsman; Michela Serresi; Ellen Tanger; Marleen Blom; Conchita Vens; Maarten van Lohuizen; Heinz Jacobs; Elisabetta Citterio
Journal:  J Exp Med       Date:  2014-08-11       Impact factor: 14.307

10.  Synergy between Non-Thermal Plasma with Radiation Therapy and Olaparib in a Panel of Breast Cancer Cell Lines.

Authors:  Julie Lafontaine; Jean-Sébastien Boisvert; Audrey Glory; Sylvain Coulombe; Philip Wong
Journal:  Cancers (Basel)       Date:  2020-02-04       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.